Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Operating Expenses (2016 - 2025)

Spyre Therapeutics' Operating Expenses history spans 11 years, with the latest figure at $57.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 6.66% year-over-year to $57.2 million; the TTM value through Dec 2025 reached $209.6 million, changed 0.48%, while the annual FY2025 figure was $209.6 million, 0.48% changed from the prior year.
  • Operating Expenses reached $57.2 million in Q4 2025 per SYRE's latest filing, roughly flat from $56.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $159.9 million in Q2 2023 to a low of $18.2 million in Q1 2021.
  • Average Operating Expenses over 5 years is $41.6 million, with a median of $33.9 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 593.92% in 2023, then plummeted 72.4% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $24.1 million in 2021, then dropped by 19.75% to $19.3 million in 2022, then skyrocketed by 137.53% to $45.9 million in 2023, then surged by 33.41% to $61.3 million in 2024, then fell by 6.66% to $57.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Operating Expenses are $57.2 million (Q4 2025), $56.9 million (Q3 2025), and $41.9 million (Q2 2025).